Anti-CD19 IgG Antibody

• Background:

  B-lymphocyte antigen CD19 (Cluster of Differentiation 19), also known as B-Lymphocyte Surface Antigen B4 and CVID3C, is a transmembrane protein expressed in follicular dendritic cells and all B lineage cells except plasma cells. CD19 plays two major roles in human B cells. It acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane and it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development and lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies. CD19-targeted therapies based on T cells that express CD19-specific chimeric antigen receptors (CARs) have been utilized for their antitumor abilities in patients with CD19+ lymphoma and leukemia, such as Non-Hodgkins Lymphoma (NHL), CLL and ALL

• Description:

  This purified recombinant monoclonal antibody is a human Anti-CD19 IgG which recognizes CD19 antigen. The variable regions for this antibody are based on an FDA-approved drug. This antibody has been tested for specific binding affinity to purified human CD19 protein (BPS Bioscience, #101015) in a colorimetric ELISA binding assay.

• UniProt:

  P15391

• Applications:

  The anti-CD19 IgG format antibody can be used for labeling cells expressing CD19 for flow cytometry and immunofluorescence microcopy.

• Purification:

  Protein A affinity purification from HEK293 cells.

• Purity:

  ≥ 90%

• Shipping Conditions:

  -80°C

• Storage Conditions:

  At least 12 months at -80°C.

• Calculated Molecular Weight:

  HC: ~49.9 kDa; LC: ~23.9 kDa

• Formulation:

  8 mM phosphate pH 7.4,110 mM NaCl, 2.2 mM KCl, 20% glycerol

• CAS Number:

  9007-83-4